Your trusted source for investing success

Tag: UK

What is Medical Device Security?

What is Medical Device Security?

The bigger problem is when these attacks are against healthcare companies carrying millions of patients personal information; the attacks can lead to postponed surgeries, leaking information or even shutting down entire computer networks in hospitals.

Gemphire Announces Pricing of $22 Million Public Offering of Common Stock

Gemphire Therapeutics (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia, Non Alcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis, announced the pricing of its previously announced underwritten public offering of 3,142,858 shares of its common stock at a public offering price of $7.00

Denali Therapeutics and Lonza Pharma & Biotech Announce Exclusive Partnership

Lonza Pharma & Biotech and Denali Therapeutics (NASDAQ:DNLI) announced an exclusive strategic partnership on Denali’s biologic pipeline products for neurodegenerative diseases. The agreement covers all stages of the development and manufacturing.

As quoted in the press release:
Through this partnership Denali will have access to Lonza’s extensive expertise and technologies: from cell-line

Zenyatta Will Focus Future Efforts on Value-Added Graphene Converted from Albany Graphite in a Vertically Integrated Structure

Zenyatta Ventures Ltd. (“Zenyatta” or “Company”) (TSXV:ZEN) is pleased to announce a strategic focus on the extraordinary nanomaterial called graphene, which is easily converted from the Company’s highly crystalline Albany graphite deposit.  Graphene is emerging as the most promising new material in modern times for enhancing applications in various industries

Ezutromid Significantly Reduced Muscle Damage in DMD Patients in 24-Week Interim Data From Summit’s PhaseOut DMD Clinical Trial

Summit Therapeutics (NASDAQ:SMMT) the drug discovery and development company advancing therapies for rare diseases and infectious diseases, today announces positive 24-week interim results from the open-label Phase 2 proof of concept clinical trial, PhaseOut DMD. PhaseOut DMD is evaluating the utrophin modulator ezutromid in patients with Duchenne muscular dystrophy.

As quoted

Enter Your Log In Credentials
This setting should only be used on your home or work computer.


Privacy & Legal Policy

Privacy Policy

Investing News Network

Send this to a friend

I thought you might find this interesting:
What is Medical Device Security?